LY2940094

DRUG4 trials

Sponsors

BlackThorn Therapeutics, Inc.

Conditions

AlcoholismDepressionMajor Depressive Disorder

Phase 1

A Study of LY2940094 in Major Depressive Disorder

CompletedNCT01263236

BlackThorn Therapeutics, Inc.Major Depressive Disorder

Start: 2010-12-31End: 2011-09-30Updated: 2017-02-03

A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects

CompletedNCT01404091

BlackThorn Therapeutics, Inc.Depression

Start: 2011-07-31End: 2011-11-30Updated: 2017-02-03

Phase 2

Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)

CompletedNCT01724112

BlackThorn Therapeutics, Inc.Major Depressive Disorder

Start: 2012-11-30End: 2014-03-31Updated: 2017-02-03

A Study of LY2940094 in Participants With Alcohol Dependency

CompletedNCT01798303

BlackThorn Therapeutics, Inc.Alcoholism

Start: 2013-07-31End: 2014-06-30Updated: 2017-02-03